B

Bergenbio ASA
OSE:BGBIO

Watchlist Manager
Bergenbio ASA
OSE:BGBIO
Watchlist
Price: 7.4 NOK 5.71% Market Closed
Market Cap: 300.5m NOK
Have any thoughts about
Bergenbio ASA?
Write Note

P/E
Price to Earnings

-1.9
Current
-416.6
Median
23
Industry
Higher than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-1.9
=
Market Cap
289.2m NOK
/
Net Income
-155.4m NOK
All Countries
Close
Market Cap P/E
NO
Bergenbio ASA
OSE:BGBIO
289.2m NOK -1.9
FR
Pharnext SCA
OTC:PNEXF
6T USD -175 931.2
US
Abbvie Inc
NYSE:ABBV
352.5B USD 69.4
US
Amgen Inc
NASDAQ:AMGN
174.8B USD 41.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
133.2B USD -277.5
US
Gilead Sciences Inc
NASDAQ:GILD
120.3B USD 955
US
Epizyme Inc
F:EPE
94.1B EUR -485.6
AU
CSL Ltd
ASX:CSL
137.9B AUD 34.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
91.2B USD 19.6
US
Seagen Inc
F:SGT
39.3B EUR -56.2
NL
argenx SE
XBRU:ARGX
33.2B EUR -128.3
Earnings Growth
NO
B
Bergenbio ASA
OSE:BGBIO
Average P/E: 223.9
Negative Multiple: -1.9
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -175 931.2 N/A
US
Abbvie Inc
NYSE:ABBV
69.4
412%
US
Amgen Inc
NASDAQ:AMGN
41.3
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -277.5
42%
US
Gilead Sciences Inc
NASDAQ:GILD
955
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -485.6 N/A
AU
CSL Ltd
ASX:CSL
34.4
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.6
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.2 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -128.3 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-1.3
2-Years Forward
P/E
-1.2
3-Years Forward
P/E
-1.3

See Also

Discover More